ClinicalTrials.gg
CompletedNCT01593046Updated Feb 10, 2014

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

A Phase 1 interventional study of GSK1265744 Oral and GSK1265744 LAP 800mg intramuscular injection in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

LAI115428 is a Phase I, randomized, repeat dose escalation study to determine the safety, tolerability, and PK profile of intramuscular and subcutaneous injections of GSK1265744 in a long acting parenteral (LAP) formulation in healthy subjects. Subjects will be randomized to 3 monthly dosing cohorts and 1 quarterly dosing cohort with either intramuscular or subcutaneous dosing. In the monthly dosing cohorts subjects will receive GSK1265744 alone for 2 months and then in combination with TMC278 long acting parenteral (LA) for 2 months. For the quarterly dosing cohort, 2 quarterly intramuscular doses of GSK1265744 LAP will be given alone. Three dose levels of GSK1265744 will be evaluated partly in combination with TMC278 LA to adequately characterize the GSK1265744 LAP and TMC278 LA safety, tolerability, and PK profile. A total enrolment of approximately 40 healthy subjects is planned for this study.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus

Keywords

  • GSK1265744 LAP
  • integrase inhibitor
  • healthy subjects
  • TMC278 LA
  • GSK1265744LAP
  • long acting retroviral
  • HIV-1 infection
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 43 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , ALT, alkaline phosphatase and greater than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female between 18 and 64 years of age inclusive, at the time of signing the .
  • Females of with a negative pregnancy test (serum or urine) at screen and at Day -21, and agrees to use one of the methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception for six months after the final dose of study drug.
  • Body weight greater than or equal to 50 kg for men and greater than or equal to 45 kg for women and (BMI) within the range 18.5-31.0 kg/m2 (inclusive).
  • All Study subjects should be counseled on the practice of safer sexual practices including the use of effective barrier methods (e.g. male condom/spermicide).

Exclusion criteria

Exclusion Criteria:

  • History of bleeding or clotting disorders including disseminated intravascular coagulation, hemophilia Henoch-Schönlein purpura (allergic purpura), hereditary hemorrhagic telangiectasia, thrombocytopenia, thrombophilia or Von Willebrand's disease.
  • High-risk behavior for infection including one of the following risk factors within six months before entering the study (day 1): Unprotected vaginal or anal sex with a known HIV infected person or a casual partner, engaged in sex work for money or drugs, acquired a sexually transmitted disease, high risk partner currently or in the previous six months.
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A positive pre-study (screening and Day -21) drug/alcohol screen.
  • History of regular alcohol consumption within 6 months of the study as defined in the protocol.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Refrain from use of prescription or non-prescription drugs, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. If heparin is used during PK sampling, subjects with a history or sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  • The subject has an underlying skin disease or disorder (i.e. infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria. Mild cases of localized acne or folliculitis are not exclusionary.)
  • The subject has a tattoo or other dermatological condition overlying the gluteus and/or abdominal region which may interfere with interpretation of injection site reactions.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Subject is mentally or legally incapacitated.
  • The subject's systolic blood pressure is outside the range of 90-140mmHg, or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects or 45-100 bpm for male subjects.
  • History of cardiovascular disease.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Run-in Period

    Oral GSK1265744 30mg once daily for 14 days

    Drug: GSK1265744 Oral

  • Experimental
    Cohort 1

    GSK1265744 LAP injection given subcutaneously once a month for 4 months

    Drug: GSK1265744 LAP 800mg intramuscular injection · Drug: GSK1265744 LAP 200mg subcutaneous injection

  • Experimental
    Cohort 2

    GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.

    Drug: GSK1265744 LAP 800mg intramuscular injection · Drug: GSK1265744 LAP 200mg intramuscular injection · Drug: TMC278 LA 1200mg intramuscular injection · Drug: TMC278 LA 600mg intramuscular injection

  • Experimental
    Cohort 3

    GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.

    Drug: GSK1265744 LAP 800mg intramuscular injection · Drug: GSK1265744 LAP 400mg intramuscular injection · Drug: TMC278 LA 1200mg intramuscular injection · Drug: TMC278 LA 600mg intramuscular injection

  • Experimental
    Cohort 4

    GSK1265744 LAP injection given intramuscularly once every 12 weeks.

    Drug: GSK1265744 LAP 800mg intramuscular injection

Interventions

06

What researchers measure

Primary outcomes

  1. GSK1265744 LAP safety and tolerability parameters including the collection of adverse events

    Time frame: approximately 25 weeks

  2. GSK1265744 LAP safety and tolerability parameters including change from baseline in clinical laboratory safety assessments

    Hematology, Clinical Chemistry and Urinalysis

    Time frame: approximately 25 weeks

  3. GSK1265744 LAP safety and tolerability parameters including change from baseline in electrocardiogram (ECG) measurements

    Time frame: approximately 25 weeks

  4. GSK1265744 LAP safety and tolerability parameters including change from baseline in vital sign measurements

    Blood pressure and heart rate

    Time frame: approximately 25 weeks

  5. TMC278 LA safety and tolerability parameters including the collection of adverse events

    Time frame: approximately 12 weeks

  6. TMC278 LA safety and tolerability parameters including change from baseline in clinical laboratory safety assessments

    Hematology, Clinical Chemistry and Urinalysis

    Time frame: approximately 12 weeks

  7. TMC278 LA safety and tolerability parameters including change from baseline in ECG measurements

    Time frame: approximately 12 weeks

  8. TMC278 LA safety and tolerability parameters including change from baseline in vital sign measurements

    Blood pressure and heart rate

    Time frame: approximately 12 weeks

  9. Composite of PK parameters following single and repeat dose intramuscular or subcutaneous administration

    Measurements include: area under the plasma concentration time curve over the dosing interval (AUC(0-t)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ct).

    Time frame: approximately 25 weeks

  10. Composite of GSK1265744 pharmacokinetic parameters following repeat dose oral administration

    Measurements include: area under the plasma concentration time curve over the dosing interval (AUC(0-t)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ct).

    Time frame: approximately 25 weeks

  11. Composite of TMC278 LA pharmacokinetic parameters following single and repeat dose intramuscular administration

    Measurements include: area under the plasma concentration time curve over the dosing interval (AUC(0-t)), maximum observed concentration (Cmax), time to maximum observed concentration (tmax), concentration at the end of the dosing interval (Ct).

    Time frame: approximately 12 weeks

  12. GSK1265744 LAP safety and tolerability parameters including change from baseline for clinical chemistry assessments (ALT, AST, ALP, Total and Direct Bilirubin).

    Time frame: 52 weeks

Secondary outcomes

  1. GSK1265744 oral formulation safety and tolerability parameters including the collection of adverse events

    Time frame: 21 days

  2. GSK1265744 oral formulation safety and tolerability parameters including change from baseline in clinical laboratory safety assessments

    Hematology, Clinical Chemistry and Urinalysis

    Time frame: 21 days

  3. GSK1265744 oral formulation safety and tolerability parameters including change from baseline in ECG measurements

    Time frame: 21 days

  4. GSK1265744 oral formulation safety and tolerability parameters including change from baseline in vital sign measurements

    Blood pressure and heart rate

    Time frame: 21 days

  5. Composite of PK parameters of GSK1265744 LAP and TMC278 LA

    Measurements include: apparent clearance (CL/FLAP) following single and repeat dose administration.

    Time frame: approximately 12 weeks

  6. Composite of PK parameters following each dose administration at different dose levels for the assessment of dose proportionality and relative exposure

    Measurements include: GSK1265744 LAP AUC(0-t), Cmax, and Ct

    Time frame: approximately 25 weeks

  7. Composite of PK parameters for GSK1265744 LAP

    Measurements include: apparent terminal phase half-life for LAP administration (t½), lambda z as a measure of absorption rate constant if data allow

    Time frame: approximately 25 weeks

  8. Composite of PK parameters of TMC278 LA

    Measurements include: AUC(0-t), Cmax, and Ct in cohort 2 and 3

    Time frame: approximately 12 weeks

07

Study locations

2 sites
  • GSK Investigational Site
    Daytona Beach, Florida 32117, United States
  • GSK Investigational Site
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2012
First posted
May 7, 2012
Start
May 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01593046
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 7, 2012
Start date
May 2012
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Feb 10, 2014

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion